Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis.
Sun U Kwon, Keun-Sik Hong, Dong-Wha Kang...
https://pubmed.ncbi.nlm.nih.gov/21799173/Actively Recruiting
Led by Tokyo Women's Medical University · Updated on 2026-11-03
270
Participants Needed
42
Research Sites
39 weeks
Total Duration
Researchers are evaluating whether pemafibrate can help prevent worsening of intracranial arterial stenosis ICAS in people who have symptomatic ICAS and high triglyceride levels after an ischemic stroke or transient ischemic attack TIA. This open-label, randomized, parallel-group trial compares a group receiving pemafibrate with a group not receiving it, while all participants continue standard stroke care including antithrombotic therapy and management of vascular risk factors. The study is sponsored by Tokyo Womens Medical University. Participants assigned to the pemafibrate group will take the drug for 12 months, with possible dose adjustments based on triglyceride levels and kidney function. Both groups will receive standard medical therapy. Brain CT angiography CTA will be performed at the start and after 12 months. Additional assessments include brain MRIMRA and vascular tests such as ankle brachial index, cardio ankle vascular index, and pulse wave velocity, conducted according to the study schedule. During the study, participants will have blood tests and clinical assessments at baseline and follow-up visits. Researchers will monitor vascular events, functional outcomes, and adverse events over 12 months. The main outcome measured is progression of intracranial arterial stenosis on CTA at 12 months. Secondary outcomes include changes in stenosis severity, cardiovascular events, mortality, daily living activities, brain imaging markers, vascular indices, blood biomarkers, and safety measures throughout the treatment period.
CONDITIONS
Pemafibrate for Symptomatic ICAS RCT
K
Kenichi Todo, MD, PhD
T
Takao Hoshino, MD, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Tokyo Women's Medical University
Lead Sponsor
Kowa Company, Ltd.
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 months
Participants receive either pemafibrate alongside standard medical therapy or standard medical therapy alone for 12 months. Dose adjustments may be made based on triglyceride levels and kidney function.
Regular visits for blood tests, clinical assessments, and imaging
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Sun U Kwon, Keun-Sik Hong, Dong-Wha Kang...
https://pubmed.ncbi.nlm.nih.gov/21799173/Sun U Kwon, Yong-Jin Cho, Ja-Seong Koo...
https://pubmed.ncbi.nlm.nih.gov/15746463/Marc I Chimowitz, Michael J Lynn, Harriet Howlett-Smith...
https://pubmed.ncbi.nlm.nih.gov/15800226/K S Wong, W W Lam, E Liang...
https://pubmed.ncbi.nlm.nih.gov/8650718/Tokyo Women's Medical University
Lead Sponsor
Kowa Company, Ltd.
Collaborating Sponsor